StemCell Therapy

SALT LAKE CITY, May 26, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announcedits Australian subsidiary has completed over 50% of participant randomization in the Phase 2 RESCUE-ALS study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The RESCUE-ALS study is substantially funded by FightMND.

The randomized, double-blind, multi-center RESCUE-ALS study is an ongoing study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in early symptomatic ALS patients. The study has to date enrolled 26 subjects of 42 planned participants.

"Enrollment in this Phase 2 study is ahead of schedule and clearly emphasizes the unmet medical need in this devasting disease. In preclinical models of ALS, CNM-Au8 has been shown to promote neuroprotection and reduce neurodegeneration. We believe the unique mechanism of CNM-Au8 provides the potential to be an effective disease-modifying therapy for patients with ALS and we look forward to completing enrollment," said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.

"We are excited to achieve this enrollment milestone for our Phase 2 RESCUE-ALS trial and believe we are on track to complete full enrollment in the third quarter of this year," said Rob Etherington, President and CEO of Clene.

About RESCUE-ALS

RESCUE-ALS is Phase 2 multi-center randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic ALS (within 24-months of screening or 12-months from diagnosis) and with a clinically probable or possible or definite ALS diagnosis. Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 30 mg or placebo in addition to their current standard of care. Participants will receive their randomized oral treatment daily over 36 consecutive weeks during the Treatment Period. The treatment is taken by mouth once daily first thing every morning. The objective of this study is to assess bioenergetic catalysis with CNM-Au8 to slow disease progression in patients with ALS.

About CNM-Au8

CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted nanocrystalline gold (Au) that acts catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of gold atoms organized into faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteersand both remyelination and neuroprotection effects in multiple preclinical models. Preclinical data presented at scientific congresses demonstrated that treatment with CNM-Au8 in neuronal cultures improved survival of neurons, protected neurite networks, decreased intracellular levels of reactive oxygen species, and improved mitochondrial capacity in response to cellular stress, induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in a rodent models of ALS, multiple sclerosis, and Parkinson's disease versus vehicle (placebo). CNM-Au8 has received regulatory approval to proceed to clinical studies for the treatment of remyelination failure in patients with multiple sclerosis and neuroprotection in patients with amyotrophic lateral sclerosis(ALS) and Parkinson's disease.

About Amyotrophic Lateral Sclerosis (ALS)

ALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About Clene

Clene Nanomedicine, Inc. is a privately-held, clinical-stage biopharmaceutical company, focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

About FightMND

FightMND is a not-for-profit registered charity, founded in 2014. It was established to raise the awareness of Motor Neurone Disease (MND) in Australia, to increase funding for research to find an effective treatment and cure and to provide care equipment for MND patients. We have a clear objective to a have a world free from MND.

FightMND is Australia's largest independent MND foundation focused on funding large- scale, collaborative research and clinical trials. The generous donations contributed by everyday Australians, right across the country, has enabled FightMND to raise and commit millions to cure and care initiatives.

Investor Contact

Kaitlyn BroscoThe Ruth Group646-536-7032[emailprotected]

Media Contact

Kirsten ThomasThe Ruth Group508-280-6592[emailprotected]

SOURCE Clene Nanomedicine, Inc.

clene.com

Go here to read the rest:
Clene Nanomedicine Announces Over 50% of Subjects Randomized in RESCUE-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS) with...

New York City, United States Since the COVID-19 infection flare-up in December 2019, the malady has spread to right around 100 nations around the world with the World Health Organization proclaiming it a general wellbeing crisis. The worldwide effects of the coronavirus sickness 2019 (COVID-19) are now beginning to be felt, and will essentially influence the Healthcare Industry in 2020.

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/14305

Company Profiles

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/14305

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs.

Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care.

A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer.

Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities.

This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/14305

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market.

Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Pressure Guidewires MarketPressure Guidewire Market Segmented By Flat Tipped Pressure Guidewires, Flexible Tipped Pressure Guidewires Product with Pressure Wire Technology, Optical Fiber Technology Type for Hospitals, Ambulatory Surgical Centers, Independent Catheterization Labs.For More Information

Compression Therapy Devices MarketThe compression therapy market of North America is projected to escalate from US$ 2,377.8 Mn in 2014 to US$ 1,515.4 Mn, registering a CAGR of 5.4% by 2020-end.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to read the rest:
Triple Negative Breast Cancer Treatment Market Covid-19 Impact In 2026 | In-depth Analysis, Global Market Share, Top Trends, Professional &...

The research report on theNanorobots marketis a specialized and in-depth industry research dealing with all technical and profitable business outlook. In the dossier all the historical and current trends of Nanorobots market is discussed comprehensively. It also showcases the trends that are anticipated for the Nanorobots market during the forecast period.

The industry statistics that are encompassed within this report is not only global but also deals with regional and country analysis. This helps the user acquire an extensive perspective about the Nanorobots market. The statistical data that is provided is further supported with thorough qualitative information. The aspects that directly or indirectly impact the Nanorobots market are exemplified through attributes such as drivers, restraints, opportunities, and the market challenges.

FREE Request Sample is Available@https://www.marketdataanalytics.biz/global-nanorobots-market-industry-trends-and-forecast-to-2027-19156.html#request-sample

The research study encompasses all the trusted models and industry analysis which prove useful for the market players to plan out the business strategies that will further help for the market development. The report also offers exhaustive competitive landscape of the market players. The major market players that are incorporated within this report areBruker, Jeol, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Ev Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging, Novascan Technologies, Angstrom Advanced, Hummingbird Scientific, Nt-Mdt Spectrum Instruments, Witec.

The market segments that are included in the report are{Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based}; {Nanomedicine, Biomedical}. Along with major segments the sub-segments of the Nanorobots market is also included. The regional segmentation of the market includes North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The major countries that are included are US, Canada, Germany, UK, China, Japan, Brazil, Mexico, among others. The study evaluates the dominance of the market in each region which helps the clients to evaluate the market demand and share on the global platform.

Read Detailed Index of full Research Study at::https://www.marketdataanalytics.biz/global-nanorobots-market-industry-trends-and-forecast-to-2027-19156.html

Details about the market players are profiled at the end. It includes all the minute information about the organization such as its headquarter location, the sales and the production details, recent product developments, and the company strategies.

Main market perceptions consist of the following:

1. The survey of Nanorobots delivers market size and growth rate for the forecast period 2020-2026.

2. It presents detailed understandings into ongoing industry trends, trend prediction, and growth drivers about the Nanorobots.

3. It offers an independent review of market sectors and the regional outlook of Nanorobots.

4. The report provides a detailed overview of the supplier landscape, combative analysis, and key market strategies to gain an advantage on competing companies.

For Any Query Regarding the Nanorobots Market Report? Contact Us at:https://www.marketdataanalytics.biz/global-nanorobots-market-industry-trends-and-forecast-to-2027-19156.html#inquiry-for-buying

See more here:
Coronavirus (COVID-19) Impact On Global Nanorobots Market 2020 Analysis By Top Key Players Bruker, Jeol, Thermo Fisher, Ginkgo Bioworks, Oxford...

As the world grapples with the continuing challenges of the Covid-19 pandemic, a multi-institutional initiative has been formed to support a broad range of research aimed at addressing the devastation to global public health, including projects by six MIT faculty.

Called the Massachusetts Consortium on Pathogen Readiness (MassCPR), and based at Harvard Medical School (HMS), it was conceived to both battle the myriad effects of SARS-CoV-2 and prepare for future health crises. Now, MassCPR has announced more than $16.5 million in funding to support 62 research projects, all with the potential for significant impact in fighting the pandemic on several fronts.

MassCPR includes scientists and clinicians from Harvard, MIT, Boston University, Tufts University, and the University of Massachusetts, as well as local biomedical research institutes, biotech companies and academic medical centers. The projects selected in the initial round of funding were based on the MassCPRs primary scientific and clinical focus areas: the development of vaccines, therapies and diagnostic tools, clinical management, epidemiology and understanding how SARS-CoV-2 causes disease.

Of the projects selected, six are led by MIT faculty:

Lee Gehrke, the Hermann von Helmholtz Professor of Health Sciences and Technology, MIT Institute for Medical Engineering and Science (IMES), a professor at HMS and a member of the faculty at the Harvard-MIT Health Sciences and Technology program (HST), will receive funding for work to develop a simple and direct antigen rapid test for SARS-CoV-2 infections. A Cambridge-based startup, E25Bio, which is using technology developed by Gerhke, has been working on a paper-based test that can deliver results in under half an hour. Gehrke, the CTO of E25Bio, says that the funding will help to accelerate the final stages of producing and introducing this test into patient care. We have been working on diagnostic tests overall for over 10 years, Gehrke says. We started working on a Covid test as soon as the news came of potential danger back in January. Gehrke says that the test is manufacturing-ready and that they have conducted small-scale manufacturing runs with a local Massachusetts-based company that will be able to scale up once clinical tests are complete. E25Bio has submitted the test to the FDA for emergency use authorization.

Angela Belcher, head of the Department of Biological Engineering, the James Mason Crafts Professor of Biological Engineering and Materials Science and Engineering, and a member of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research, will also receive support for her research proposal, Novel nanocarbon materials for life-development of distributable textiles that filtrate/neutralize dangerous viruses/bacteria to protect medical professional and civilians from virus pandemic disease.

Jianzhu Chen, a professor in the Department of Biology, also a member of the Koch Institute, was selected for a project focusing on enhancing mRNA-based coronavirus vaccines with lymph node-targeted delivery and neutralizing antibody-inducing adjuvant. Chen says that the grant will help fund proposed research aimed at devising an effective vaccine, and that the money will help us to jumpstart our research on SARS-CoV-2, as well as vaccines to address other pathogens.

Bruce Walker, professor of the practice at IMES and the Department of Biology, founding director of the Ragon Institute of MGH, MIT, and Harvard, and Phillip T and Susan M Ragon Professor of Medicine at Harvard Medical School, will receive support for research on A highly networked, exosome-based SARS-CoV-2 vaccine.

Feng Zhangs project, Development of a point-of-care diagnostic for COVID-19, was also selected. Zhang is the James and Patricia Poitras Professor of Neuroscience and a professor of brain and cognitive sciences and biological engineering at MIT, an investigator at the McGovern Institute for Brain Research, and a core member of the Broad Institute of MIT and Harvard.

Siqi Zheng, the Samuel Tak Lee Associate Professor in the Department of Urban Studies and Planning and faculty director of the Center for Real Estate will receive funding for research on quantifying the role of social distancing in shaping the Covid-19 curve: incorporating adaptive behavior and preference shifts in epidemiological models using novel big data in 344 Chinese cities. Zheng calls the funding crucial in research that will compare different regions and how people react to social and physical distancing during a pandemic, and will examine various government policies aimed at controlling the spread of the virus.

The rest is here:
Six from MIT awarded research funding to address Covid-19 - MIT News

Global Nanorobotics Marketwas valued at US$ 3.7 Bn in 2018 and is expected to reach US$ 9.2Bn by 2026, at a CAGR of 12.06%during a forecast period.

Developments in nanotechnology coupled with demand for minimally aggressive procedures are expected to drive market growth over the forecast period. Nanobots possess likely in the medical sector for destroying cancerous cells at the genetic level. Increasing support for nanomedicine by many nations and the increasing geriatric population are factors which can augur market demand.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/30888

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Utilization of nanobots in the ranostics can be beneficial for the market in the near future. A rise in miniaturization and demand for automation across various sectors are anticipated to fuel market growth. Training of new personnel to use nanobots can restrain market growth in the upcoming years.Nanomedicine application segment to grow at the highest CAGR during the forecast period. Nanorobotics is widely used in nanomedicine owning to its healthcare features. The large share of this application aspects to the large level of commercialization in the healthcare sector for drug delivery, in vivo imaging, biomaterial, in vitro diagnostic, active implants, and drug therapy.

North America region accounted for the largest share of 12.2%, in terms of value, of the nanorobotics market globally. Presence of many nanotechnology companies, well-developed healthcare infrastructure, and government initiatives to create patient awareness are factors driving the market. The U.S is anticipated to contribute to market revenue owing to the increase in cardiovascular diseases and the rising elderly populace.

Europe follows North America as the second biggest nanorobotics market. Presence of chronic diseases and the burgeoning population are factors expected to indicate the Europe nanobots market. Establishment of organizations to develop standards pertaining to nanotechnology can expand market growth. In 2018, DNA-Robotics, an organization including 12 European companies, has outlined steps to expedite production of nanobots on a large scale. These standards can help scale the market exponentially in the upcoming years.

A recent development in nanorobotics market: In March 2018, Thermo Fisher Scientific acquired Gatan, an exclusively owned subsidiary of Roper Technologies. Gatan is an electron microscopy solutions provider in the U.S, which accompaniments the Thermo Fisher Scientifics electron microscopy solutions business.In March 2017, Oxford Instruments (U.K) Asylum Research introduced its new SurfRider HQ-Series of high quality, budget-priced AFM probes, which are also existing in a model suitable for nanomechanical image mode.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Nanorobotics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global Nanorobotics Market.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/30888

Scope of the Global Nanorobotics Market

Global Nanorobotics Market, By Type

Nanomanipulatoro Electron Microscope (EM) Scanning Electron Microscope (SEM) Transmission Electron Microscope (TEM)o Scanning Probe Microscope (SPM) Atomic Force Microscopes (AFM) Scanning Tunneling Microscope (STM) Bio-Nanorobotics Magnetically Guided Bacteria-BasedGlobal Nanorobotics Market, By Application

Nanomedicine Biomedical Mechanical OthersGlobal Nanorobotics Market, By Region

North America Europe Asia Pacific Middle East and Africa South AmericaKey players operating in Global Nanorobotics Market:

Bruker JEOL Thermo Fisher Scientific Ginkgo Bioworks Oxford Instruments EV Group Imina Technologies Toronto Nano Instrumentation KlockeNanotechnik KleindiekNanotechnik Xidex Synthace Park Systems Smaract Nanonics ImagingKey Innovators:

Novascan Technologies Angstrom Advanced Hummingbird Scientific NT-MDT Spectrum Instruments Witec

MAJOR TOC OF THE REPORT

Chapter One: Nanorobotics Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanorobotics Market Competition, by Players

Chapter Four: Global Nanorobotics Market Size by Regions

Chapter Five: North America Nanorobotics Revenue by Countries

Chapter Six: Europe Nanorobotics Revenue by Countries

Chapter Seven: Asia-Pacific Nanorobotics Revenue by Countries

Chapter Eight: South America Nanorobotics Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanorobotics by Countries

Chapter Ten: Global Nanorobotics Market Segment by Type

Chapter Eleven: Global Nanorobotics Market Segment by Application

Chapter Twelve: Global Nanorobotics Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanorobotics Market Report at:https://www.maximizemarketresearch.com/market-report/global-nanorobotics-market/30888/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Continue reading here:
Global Nanorobotics Market : Industry Analysis and Forecast (2019-2026) by Type, Application, and... - Azizsalon News

The Nano Colloidal Copper market research encompasses an exhaustive analysis of the market outlook, framework, and socio-economic impacts. The report covers the accurate investigation of the market size, share, product footprint, revenue, and progress rate. Driven by primary and secondary researches, the Nano Colloidal Copper market study offers reliable and authentic projections regarding the technical jargon.All the players running in the global Nano Colloidal Copper market are elaborated thoroughly in the Nano Colloidal Copper market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Nano Colloidal Copper market players.The report on the Nano Colloidal Copper market provides a birds eye view of the current proceeding within the Nano Colloidal Copper market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Nano Colloidal Copper market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2576036&source=atm

The following manufacturers are covered:Purest ColloidsStarmedSom PhytopharmaNanjing XFNANO MaterialsNatural ImmunogenicsMinerals TechnologiesAma Resources

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeElectron GradeIndustrial GradeMedicine Grade

Segment by ApplicationLubricating Oil AdditiveFood AdditiveOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2576036&source=atm

Objectives of the Nano Colloidal Copper Market Study:To define, describe, and analyze the global Nano Colloidal Copper market based on oil type, product type, ship type, and regionTo forecast and analyze the Nano Colloidal Copper market size (in terms of value and volume) and submarkets in 5 regions, namely, APAC, Europe, North America, Central & South America, and the Middle East & AfricaTo forecast and analyze the Nano Colloidal Copper market at country-level for each regionTo strategically analyze each submarket with respect to individual growth trends and their contribution to the global Nano Colloidal Copper marketTo analyze opportunities in the market for stakeholders by identifying high growth segments of the global Nano Colloidal Copper marketTo identify trends and factors driving or inhibiting the growth of the market and submarketsTo analyze competitive developments, such as expansions and new product launches, in the global Nano Colloidal Copper marketTo strategically profile key market players and comprehensively analyze their growth strategiesThe Nano Colloidal Copper market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Nano Colloidal Copper market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Nano Colloidal Copper market study provides reliable and authentic projections regarding the technical jargon.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2576036&licType=S&source=atm

After reading the Nano Colloidal Copper market report, readers can:Identify the factors affecting the Nano Colloidal Copper market growth drivers, restraints, opportunities and trends.Examine the Y-o-Y growth of the global Nano Colloidal Copper market.Analyze trends impacting the demand prospect for the Nano Colloidal Copper in various regions.Recognize different tactics leveraged by players of the global Nano Colloidal Copper market.Identify the Nano Colloidal Copper market impact on various industries.

Read more:
Assessing the Fallout From the Coronavirus Pandemic Nano Colloidal Copper Market Current and Future Trends, Leading Players, Industry Segments and...

CALGARY, Alberta, May 11, 2020 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the Company or Voyageur) is pleased to announce it has signed an LOI with an established international mining company (the Counterparty) that has developed a low cost method to extract the natural occurring carbon molecule, C-60 to C-90, from large natural-occurring fullerene resources.

The technology to extract C-60 from natural fullerene deposits is ground-breaking and a first in this industry. Voyageur will be the first company to be able to mass produce C-60 at a low cost, allowing for multiple drug products to be developed, states Brent Willis, CEO of Voyageur Pharmaceuticals.

The barriers for C-60 based drugs has now been broken, which opens up the industry to develop new effective drugs and health care products on an economic scale, continues Brent Willis.

The API, C-60, is a natural, highly effective super antioxidant, like more common antioxidants (Vitamin C, Vitamin A and Selenium). It scavenges toxic free radicals but it stands out as a notable anti-aging innovation because it selectively scavenges the reactive oxygen species that do the most damage to humans as opposed to just working by osmosis like a normal antioxidant. The anti-aging properties are exciting, as studies in animals have shown the potential to significantly extend life span and to slow the aging process.

Voyageur has begun work on its first C-60 product, C-60X, an immune system booster, natural health product, for daily consumption. Voyageur is creating a C-60 R&D Therapeutics division that will be focused on developing natural health products and drugs. For early cash flow, Voyageur will utilize our Calgary-based manufacturing partners for natural health product sales.

Highlights of C-60 Medical Applications

"Thedifficulty inprocessingof fullerenes has presented a major problem in the search for medicinal applications. This is the breakthrough thatour partner hasrecentlyovercome. The patent-pending technology that can recover economic & high volumes of C-60 from natural fullerene mineral ores is a game changer. This opens the door for Voyageur to become the only company to have the capability to develop and mass produce C-60 based drugs and natural health products at a low cost & high volume, says Brent Willis.

Voyageur plans to develop low cost C-60 radiographic contrast drugs, which encapsulate iodine, gadolinium, and other potential molecules. By utilizing C-60, we may be able to enhance the performance and create the safest radiographic contrast media in the marketplace. Studies have shown that MRI C-60 gadolinium contrast media has a gain of a 500-fold sensitivity on intravital MR Contrast Agents.

Essentially, a carbon-60 molecule is comprised of 60 carbon atoms which are arranged in a unique shape that can be thought of as a 'carbon cage' (like a soccer ball). This sphere makes it possible to be a carrier of other molecules creating a protective shield, allowing C-60 to be an excellent drug delivery vehicle in radiology and healthcare.

This drug delivery system is quite unique to the pharmaceutical industry and our company is proud to begin the innovative steps to develop unique new delivery systems, states Brent Willis.

It has long been known that effective delivery systems are of paramount importance in promoting drug efficacy. This is not only a major milestone for our Company, but potentially a major breakthrough for the entire healthcare industry, continues Willis.The significance of the technological breakthrough, to extract natural fullerene from rock, may well pave the way for a low-cost evolution in the carbon-based health care market. Voyageur is the first company to begin to break down the barrier to market. The C-60 therapeutics division will enhance our Companys ability to become more competitive in the radiographic contrast market and become a leader in the C-60 drug & natural health sector. Fullerene is a gateway for Voyageur to become a leader in a new and exciting carbon medicine field. We will continue to build our From The Earth To The Bottle strategy, to become a fully-integrated competitive force in the API mineral based pharmaceutical industry.

The signed LOI for supply exclusivity will allow Voyageur to produce low cost & high-volume natural carbon-60 API for the pharmaceutical industry. This would allow Voyageur to be fully integrated in the C-60 market and become the only low-cost producer of fullerene based health care products. Voyageur is adding C-60 to its portfolio of active pharmaceutical ingredients (API) minerals for use in the radiographic contrast media markets. There are multiple applications for Fullerene based nano medicines in the healthcare industry, which Voyageur will further research and develop.

Due to confidentiality and pending patents, Voyageur cannot disclose at this time, the identity of the Counterparty.

About Voyageur

Voyageur Pharmaceuticals Ltd. is Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barite, iodine, and fullerene Active Pharmaceutical Ingredient (API) minerals. The near-term focus is developing barium, iodine radio-contrast products and fullerene-based pharmaceutical products.

Voyageurs goal is to initially generate the positive cash flow from operations using third party GMP pharmaceutical manufacturers. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing.

Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, including interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully integrated company in the radio-contrast medical field, by controlling all primary input costs under the motto of:

"From the Earth to the Bottle"

For Further Media Information or to set up an interview, please contact:

Reader Advisory

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Statements

This news release contains certain statements or disclosures relating to the Company that are based on the expectations of its management as well as assumptions made by and information currently available to the Company which may constitute forward-looking statements or information ("forward-looking statements") under applicable securities laws. All such statements and disclosures, other than those of historical fact, which address activities, events, outcomes, results, or developments that the Companyanticipates may or will occur in the future (in whole or in part) should be considered forward-looking statement and undue reliance should not be placed on any such statements. In some cases, forward-looking statements can be identified by the use of the words "will", "intends", believes, expects, forecasts, "anticipates", "plans" and similar expressions.

In particular, but without limiting the foregoing, this news release contains forward-looking statements pertaining to the following, the certainty of the disclosed LOI being made into a formal binding agreement; the ability of Voyageur to integrate fullerene into marketable pharmaceutical and healthcare markets; the feasibility and expectation of the Company to bring into production those mining assets it has an interest in; the experience of management and directors of Voyageur and its pharmaceutical manufacturingpartners to execute on its business plan and that of its joint venture company; the economics and risks associated with its business plan; future operations and strategies for development, sales and distribution of mineral and pharmaceutical product;; the Companys ability to successfully penetrate either domestic or foreign pharmaceutical markets; the amount, quality and cost of supply of active pharmaceutical ingredients for potential pharmaceutical products; the ability for Voyageur to meet its joint venture obligations; anticipated registrations with Health Canada or similar foreign bodies for various pharmaceutical products the Company plans to develop, produce and sell; and the ability of the Company to attract investment capital to fund operations and capital expenditures.

The forward-looking statements contained in this news release are made as of the date hereof and the Company undertakes no obligations to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Source Information:

https://www.ncbi.nlm.nih.gov/pubmed/23785493/ https://phys.org/news/2019-09-fullerene-compounds-virus-infections-hiv.html, https://c60-france.com/media_upload/C60-Fullerene-nano-particles-Inhibit-HIV-Replication.pdf https://www.sesres.com/carbon-60-c60-powder/#buy_c60 https://www.sciencedirect.com/science/article/pii/S0142961212003237https://www.hindawi.com/journals/jnm/2015/565638/https://en.wikipedia.org/wiki/Fullerene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880842/ https://www.sciencedirect.com/science/article/pii/S0142961212003237 Mitsubishi https://www.azonano.com/article.aspx?ArticleID=47 https://pubs.acs.org/doi/full/10.1021/es801869m https://phys.org/news/2020-03-scientists-water-soluble-fullerene-compounds-medicine.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676811/https://pubs.acs.org/doi/10.1021/acsanm.9b01698

Continued here:
Voyageur Secures Exclusive Rights To One Of The Worlds Rarest Pharmaceutical Minerals, Creating A New Era In Carbon Based Drug Development -...

May 11, 2020 David Graves, an internationally-known chemical engineer, has been named to lead a new research enterprise that will explore plasma applications in nanotechnology for everything from semiconductor manufacturing to the next generation of super-fast quantum computers.

Graves, a professor at the University of California, Berkeley, since 1986, is an expert in plasma applications in semiconductor manufacturing. He will become the Princeton Plasma Physics Laboratorys (PPPL) first associate laboratory director for Low-Temperature Plasma Surface Interactions, effective June 1. He will likely begin his new position from his home in Lafayette, California, in the East Bay region of San Francisco.

He will lead a collaborative research effort to not only understand and measure how plasma is used in the manufacture of computer chips, but also to explore how plasma could be used to help fabricate powerful quantum computing devices over the next decade.

This is the apex of our thrust into becoming a multipurpose lab, said Steve Cowley, PPPL director, who recruited Graves. Working with Princeton University, and with industry and the U.S. Department of Energy (DOE), we are going to make a big push to do research that will help us understand how you can manufacture at the scale of a nanometer. A nanometer, one-billionth of a meter, is about ten thousand times less than the width of a human hair.

The new initiative will draw on PPPLs expertise in low temperature plasmas, diagnostics, and modeling. At the same time, it will work closely with plasma semiconductor equipment industries and will collaborate with Princeton University experts in various departments, including chemical and biological engineering, electrical engineering, materials science, and physics. In particular, collaborations with PRISM (the Princeton Institute for the Science and Technology of Materials) are planned, Cowley said. I want to see us more tightly bound to the University in some areas because that way we get cross-fertilization, he said.

Graves will also have an appointment as professor in the Princeton University Department of Chemical and Biological Engineering, starting July 1. He is retiring from his position at Berkeley at the end of this semester. He is currently writing a book (Plasma Biology) on plasma applications in biology and medicine. He said he changed his retirement plans to take the position at PPPL and Princeton University. This seemed like a great opportunity, Graves said. Theres a lot we can do at a national laboratory where theres bigger scale, world-class colleagues, powerful computers and other world-class facilities.

Exciting new direction for the Lab

Graves is already working with Jon Menard, PPPL deputy director for research, on the strategic plan for the new research initiative over the next five years. Its a really exciting new direction for the Lab that will build upon our unique expertise in diagnosing and simulating low-temperature plasmas, Menard said. It also brings us much closer to the university and industry, which is great for everyone.

The staff will grow over the next five years and PPPL is recruiting for an expert in nano-fabrication and quantum devices. The first planned research would use converted PPPL laboratory space fitted with equipment provided by industry. Subsequent work would use laboratory space at PRISM on Princeton Universitys campus. In the longer term, researchers in the growing group would have brand new laboratory and office space as a central part the Princeton Plasma Innovation Center (PPIC), a new building planned at PPPL.

Physicists Yevgeny Raitses, principal investigator for the Princeton Collaborative Low Temperature Plasma Research Facility (PCRF) and head of the Laboratory for Plasma Nanosynthesis, and Igor Kavanovich, co-principal investigator of PCRF, are both internationally-known experts in low temperature plasmas who have forged recent partnerships between PPPL and various industry partners. The new initiative builds on their work, Cowley said.

A priority research area

Research aimed at developing quantum information science (QIS) is a priority for the DOE. Quantum computers could be very powerful in solving complex scientific problems, including simulating quantum behavior in material or chemical systems. QIS could also have applications in quantum communication, especially in encryption, and quantum sensing. It could potentially have an impact in areas such as national security. A key question is whether plasma-based fabrication tools commonly used today will play a role in fabricating quantum devices in the future, Menard said. There are huge implications in that area, Menard said. We want to be part of that.

Graves is an expert on applying molecular dynamics simulations to low temperature plasma-surface interactions. These simulations are used to understand how plasma-generated ions, atoms and molecules interact with various surfaces. He has extensive research experience in academia and industry in plasma-related semiconductor manufacturing. That expertise will be useful for understanding how to make very fine structures and circuits at the nanometer, sub-nanometer and even atom-by-atom level, Menard said. Davids going to bring a lot of modeling and fundamental understanding to that process. That, paired with our expertise and measurement capabilities, should make us unique in the U.S. in terms of what we can do in this area.

Graves was born in Daytona Beach, Florida, and moved a lot as a child because his father was in the U.S. Air Force. He lived in Homestead, Florida; near Kansas City, Missouri; and in North Bay Ontario; and finished high school near Phoenix, Arizona.

Graves received bachelors and masters degrees in chemical engineering from the University of Arizona and went on to pursue a doctoral degree in the subject, graduating with a Ph.D. from the University of Minnesota in 1986. He is a fellow of the Institute of Physics and the American Vacuum Society. He is the author or co-author of more than 280 peer-reviewed publications. During his long career at Berkeley, he has supervised 30 Ph.D. students and 26 post-doctoral students, many of whom are now in leadership positions in industry and academia.

A leader since the 1990s

Graves has been a leader in the use of plasma in the semiconductor industry since the 1990s. In 1996, he co-chaired a National Research Council (NRC) workshop and co-edited the NRCs Database Needs for Modeling and Simulation of Plasma Processing. In 2008, he performed a similar role for a DOE workshop on low-temperature plasmas applications resulting in the report Low Temperature Plasma Science Challenges for the Next Decade.

Graves is an admitted Francophile who speaks (near) fluent French and has spent long stretches of time in France as a researcher. He was named Matre de Recherche (master of research) at the cole Polytechnic in Palaiseau, France, in 2006. He was an invited researcher at the University of Perpignan in 2010 and received a chaire dexcellence from the Nanoscience Foundation in Grenoble, France, to study plasma-graphene interactions.

He has received numerous honors during his career. He was appointed the first Lam Research Distinguished Chair in Semiconductor Processing at Berkeley for 2011-2016. More recently, he received the Will Allis Prize in Ionized Gas from the American Physical Society in 2014 and the 2017 Nishizawa Award, associated with the Dry Process Symposium in Japan. In 2019, he was appointed foreign expert at Huazhong University of Science and Technology in Wuhan, China. He served as the first senior editor of IEEE Transactions on Radiation and Plasma Medical Science.

Graves has been married for 35 years to Sue Graves, who recently retired from the City of Lafayette, where she worked in the school bus program. The couple has three adult children. Graves enjoys bicycling and yoga and the couple loves to travel. They also enjoy hiking, visiting museums, listening to jazz music, and going to the theater.

About PPPL

PPPL, on Princeton Universitys Forrestal Campus in Plainsboro, N.J., is devoted to creating new knowledge about the physics of plasmas ultra-hot, charged gases and to developing practical solutions for the creation of fusion energy. The Laboratory is managed by the University for the U.S. Department of Energys Office of Science, which is the largest single supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visitscience.energy.gov(link is external).

Source: Jeanne Jackson DeVoe, PPPL

See the original post here:
David Graves to Head New Research at PPPL for Plasma Applications in Industry and Quantum Information Science - HPCwire

Ming-Chen Sun,1,* Xiao-Ling Xu,1,* Xue-Fang Lou,2 Yong-Zhong Du1

1Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Peoples Republic of China; 2School of Medicine, Zhejiang University City College, Hangzhou 310015, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Yong-Zhong DuInstitute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, Peoples Republic of ChinaTel +86-571-88208435Fax +86-571-88208439Email duyongzhong@zju.edu.cnXue-Fang LouSchool of Medicine, Zhejiang University City College, 51 Hu-Zhou Street, Hangzhou 310015, Peoples Republic of ChinaTel +86-571-88013011Fax +86-571-88018442Email louxf@zucc.edu.cn

Abstract: Vitiligo is a depigmentation disease that seriously affects the physical health, mental health and quality of life of a patient. Therapeutic aim at control immunoreaction by relieving oxidative stress. Unfortunately, the cuticle barrier function and lack of specific accumulation lead to unsatisfactory therapeutic outcomes and side effects. The introduction and innovation of nanotechnology offers inspiration and clues for the development of new strategies to treat vitiligo. However, not many studies have been done to interrogate how nanotechnology can be used for vitiligo treatment. In this review, we summarize and analyze recent studies involving nano-drug delivery systems for the treatment of vitiligo, with a special emphasis on liposomes, niosomes, nanohydrogel and nanoparticles. These studies made significant progress by either increasing drug loading efficiency or enhancing penetration. Based on these studies, there are three proposed principles for topical nano-drug delivery systems treatment of vitiligo including the promotion of transdermal penetration, enhancement of drug retention and facilitation of melanin regeneration. The presentation of these ideas may provide inspirations for the future development of topical drug delivery systems that will conquer vitiligo.

Keywords: vitiligo, nano-drug delivery system, transdermal penetration, liposomes, skin

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

The rest is here:
Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press

Transportation restrictions and stringent government policies are causing a downturn in the growth scale of the Nanomedicine market amidst the COVID-19 (Coronavirus) lockdown period. Hence, analysts at Market Research Reports Search Engine (MRRSE) have collated a research study that provides an in-depth outlook on Coronavirus and how the novel virus can leave long-term effects in trade practices post lockdown period in the Nanomedicine market.

Why Choose MRRSE?

Request Sample Report @https://www.mrrse.com/sample/3117?source=atm

The report on the global Nanomedicine market published by MRRSE provides a clear understanding of the flight of the Nanomedicine market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the Nanomedicine market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Nanomedicine market are analyzed in the report.

The study reveals that the global Nanomedicine market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the Nanomedicine market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Key Takeaways of the Report:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/3117?source=atm

Nanomedicine Market Segmentation

The presented study throws light on the current and future prospects of the Nanomedicine market in various geographies such as:

The report highlights the product adoption pattern of various products in the Nanomedicine market and provides intricate insights such as the consumption volume, supply-demand ratio, and pricing models of the following products:

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

Go here to read the rest:
Potential impact of coronavirus outbreak on Nanomedicine Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts to 2024...

Technology makes processes easier, faster, safer, and more efficient. Shouldnt it, therefore, also reduce costs?

This isnt always the case. Thats because researching and developing new technology can cost millions of dollars; add to that the cost of materials and production. By the time that technology is launched, billions may have been spent developing it.

New technology has brought immense benefits to the following four industries, but it hasnt necessarily lowered costs for consumers.

Medical technology is so innovative that doctors can now insert tiny robotics into the body to repair internal wounds or remove objects. This is a branch of medicine called nanomedicine. Nanomedicine uses nanosized (even smaller than microsized) carriers to transport drugs to specific cells or tumors in the body. This form of technology opens up a new way to treat cancer, for instance. Rather than subject the entire body to chemotherapy, nanotechnology can deliver chemotherapy drugs directly to the tumor.

These types of treatments, however, dont come cheap. In fact, healthcare costs in the United States continue to rise. In 2018, the U.S spent $3.6 trillion on healthcare, which works out to an average of $11,000 per person. This is projected to increase to $18,000 per person by 2028.

One of the main drivers of escalating healthcare costs is medical technology. According to a report by The Hastings Center, healthcare economists found that 40 percent to 50 percent of annual healthcare cost increases were linked to new medical technologies.

Sustainable energy has a positive impact on the environment. Solar- and wind-powered energy mean less reliance on harmful fossil fuels for energy production. Electric cars eliminate toxic fuel emissions.

But solar panels can be costly to install, and electric cars are often more expensive to buy than traditional cars. Electric vehicles can range in pricing from $31,915 for a Nissan Leaf to $70,875 for the Jaguar I-Pace.

The good news is these products pay for themselves over time with the savings on your electric and gas bills. In addition, buying an electric car or implementing energy-saving technology in your home can make you eligible for a rebate. States like California offer rebates of up to $500 when installing solar products and up to $7,000 when buying an electric vehicle.

Many of the aviation safety systems that are standard on planes today were born from past mistakes. When an airplane crashes, a thorough investigation is conducted. The lessons learned from a catastrophic disaster often lead to improved safety technology.

The aviation industry has made giant strides in technology to make flying safer, lower the cost of fuel, and find ways to reduce airplane emissions. Engineers are looking at ways to manufacture lighter engines and using 3D printing to design and produce lighter aircraft parts. Every part that becomes lighter, even brackets and hinges, helps decrease the planes overall weight and boost fuel efficiency.

In their quest to reduce their carbon footprint, aircraft manufacturers are following the example of the automotive industry and testing electric engines for airplanes. Theyre also testing biofuels, such as sugarcane and cooking oil. According to NASA, a 50/50 blend of jet fuel and biofuel can cut soot emissions by 50 percent. While this is great for the environment, flying a plane with biofuels costs more than traditional jet fuel.

Despite new technology and lower fuel costs, travelers are unlikely to see a drop in the cost of flights. And with the COVID-19 pandemic grounding planes across the globe, many airlines are likely to try to recoup losses by charging higher fares when travel resumes.

Car safety technology, like collision avoidance systems, blind-spot monitoring, automated braking, lane keep assist, and rear-view backup cameras have become standard on most new cars.

Despite the fact that the National Highway Traffic Safety Administration and the Insurance Institute for Highway Safety agree that safety tech in cars is effective in reducing car crashes, insurance companies havent lowered their rates on cars that feature them. The only car safety technologies that lower insurance rates are electronic stability control and telematics.

If car tech helps prevent accidents, why arent insurance rates lower? Insurance companies cite the following reasons:

Technology improves our lives in many ways, but it doesnt always lower costs. In some cases, it may even increase the cost of goods or services. The tradeoff is in what we gain from new technologies: more efficiency, better safety, time-saving convenience, and less damage to the environment.

Link:
The Benefits of Tech Even Those That Don't Cut Costs - The Tech Report

Endo International

The scope of the Report:

The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Healthcare Nanotechnology (Nanomedicine) market. A competition analysis is imperative in the Healthcare Nanotechnology (Nanomedicine) market and the competition landscape serves this objective. A wide company overview, financials, recent developments, and long and short-term strategies adopted are par for the course. Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in the sales of Healthcare Nanotechnology (Nanomedicine) across the world has been calculated through primary and secondary research. The Healthcare Nanotechnology (Nanomedicine) Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=210503&utm_source=NYH&utm_medium=888

Highlights of the Healthcare Nanotechnology (Nanomedicine) market study:

Speculations for sales:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Healthcare Nanotechnology (Nanomedicine) market. Additionally, it includes a share of every segment of the Healthcare Nanotechnology (Nanomedicine) market, giving methodical information about types and applications of the market.

Key point summary of the Healthcare Nanotechnology (Nanomedicine) market report:

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It presents an in-depth analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by creating a pin-point analysis of market segments and by having complete insights of the Healthcare Nanotechnology (Nanomedicine) market.

This report helps users in comprehending the key product segments and their future.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Healthcare Nanotechnology (Nanomedicine) market

Chapter 2: Evaluating the leading manufacturers of the global Healthcare Nanotechnology (Nanomedicine) market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Healthcare Nanotechnology (Nanomedicine) market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Finally, the report global Healthcare Nanotechnology (Nanomedicine) market describes Healthcare Nanotechnology (Nanomedicine) industry expansion game plan, the Healthcare Nanotechnology (Nanomedicine) industry knowledge supply, appendix, analysis findings and the conclusion. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Report customization:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=210503&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Healthcare Nanotechnology (Nanomedicine) Market Size, Healthcare Nanotechnology (Nanomedicine) Market Trends, Healthcare Nanotechnology (Nanomedicine) Market Growth, Healthcare Nanotechnology (Nanomedicine) Market Forecast, Healthcare Nanotechnology (Nanomedicine) Market Analysis sarkari result, sarkari exam, sarkari naukri

Our Trending Reports

Offshore AUV and ROV Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Oil & Gas Analytics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

View original post here:
Healthcare Nanotechnology (Nanomedicine) Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty

It is my opinion that over the next 5 to 10 years the delivery of medicine will change dramatically. The pharmacist of the future will become the pharmacist of the past. Many years ago, before the incredible sophistication of the pharmaceutical industry, many pharmacists compounded medications in their own facility.

I foresee a situation where a person will go to the doctor following a full assessment of their own genome. A treatment plan will be formulated based on the persons own genetic abnormalities and predispositions. Rather than taking a number of separate pharmaceutical pills and, for those so inclined, vitamin supplements, the doctor will administer a personalised prescription for the person. This will be taken to their pharmacist and, using nanotechnology, all of these therapies will be delivered within the one small pill, taken once daily.

The technology would be advanced to the point where each separate medication within the nano-pill would be released at the appropriate time into the circulation. We are well aware that computer technology power doubles every 18 months and the advances in nanotechnology appear to be mirroring this.

On a separate, but similar, note, the University of Pittsburgh has released recently in the Journal of Investigative Dermatology, a fingertip patch with 400 microneedles for vaccine delivery for live or attenuated vaccines.

The microneedles are made from three-dimensional sugar structures incorporated into what is known as a multicomponent dissolving microneedle array. Interestingly, this not only induces an antibody response but also improves the cellular response better than standard vaccines given via injection. It appears from the preliminary studies that this will induce a strong and long-lasting immunity. The researchers trialled this in mice administering a live adenovirus with encoded antigens and a specific immune stimulant to enhance the local immune response.

In the last few weeks, researchers at the University of Oxford in England have started a trial of a vaccine for the Coronavirus. It may be that, in the very near future, rather than the needle jab, we are using these micro patches instead for all vaccines.

Researchers from Harvard University in the USA are also working on a similar patch technology for the management of diabetes. The patch not only delivers insulin through the skin but also measures real-time blood sugar levels.

At present, the vast majority of insulin-dependent diabetics need to constantly prick their fingers to monitor blood sugar levels and then inject themselves on multiple occasions throughout the day. Again, over the next few years, the management of diabetes will be revolutionised by the use of these micro patches.

For many chronic conditions affecting millions of people, especially over the age of 50, the future of chronic medical management is very bright. When I started medical school in the 1970s, our medical and surgical therapies were modestly effective and I have seen a revolution in the management of chronic illnesses, such as cardiovascular disease and cancer, over the past 40 to 50 years.

With these extraordinary advances mentioned above, which are only a portion of what we will see over the next decade, the future of medicine is looking very bright indeed.

Visit link:
The future of medicine - Switzer Financial News

The market research study titled Global Nanomedicine Market Size, Status and Forecast 2020-2026 brings you the most recent and the most updated data on the market. The report provides extensively researched information about the global Nanomedicine market structure, valuates, and outlines its variable aspects and applications. The report comprehensively represents the context of current and future trends driving the profit matrix. The report contains computable information, qualitative information sets, and evaluation tools. The research highlights major market insights, challenges, current trends, and value chain analysis.

The study provides estimates on global Nanomedicine market share, market size, and regional topography along with statistics, diagrams and charts explaining the differing interesting framework of the industry landscape. Divided by product type, applications, industry verticals, and research regions, the report research document delivers an explanation of the perspectives and comprehensive market statistics. It further covers the pricing of the product, production and consumption volume, cost analysis, industry value, barriers and growth drivers, major market players, demand and supply ratio of the market, the growth rate of the market and forecast from 2020 to 2026. Top players are completely profiled in this report.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/28942/request-sample

The major manufacturers covered in this report: Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences,

Regional Analysis For Market:

North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa) are leading countries and provide data like market share (%), sales (volume), imports & exports by types and applications, analysis, production, consumption, and consumption forecast. Information about different regions helps the reader to understand the global Nanomedicine market better.

Product type coverage (market size & forecast, a major company of product type etc.):

Application coverage (market size & forecast, different demand market by region, main consumer profile etc.): Segmentation encompasses oncology, Infectious diseases, Cardiology, Orthopedics, Other

Moreover, the report has included the leading merchants in this global Nanomedicine market everywhere throughout the world. In this part, market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue are determined. Additionally, upstream raw materials and downstream demand studies are administered. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The report further incorporates speculation attainability investigation and venture return investigation.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-nanomedicine-market-size-status-and-forecast-2020-2026-28942.html

Some of The Points Explained in The TOC of Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

See the original post:
Global Nanomedicine Market by Type, Application, Element, & by Region Trends and Forecast to 2026 - Jewish Life News

Researchers from IIT-Madras have developed a clove oil-based emulsion to treat cancer, claiming that the formulation would have enormous scope in the treatment of undifferentiated cancer and can also overcome anti-microbial resistance. The research papers were published recently in the reputed International Journal of Nanomedicine.The researchers, led by professor R Nagarajan, head, department of chemical engineering in IIT Madras, have developed a nano-scale emulsion of clove bud using the spontaneous self-emulsification technique with potent anti-cancer and antibacterial activity. This formulation meets all compliance requirements, they said. According to Nagarajan, while conventional therapies for cancer like radiation, chemotherapy and surgery cause severe damage to normal cells along with other major side-effects, the plant-based essential oils have paved way to devise innovative solutions to these drawbacks of synthetic drugs.The advantages of these emulsions lie in their small droplet size, ease of preparation, optical clarity, good physical stability, improved bio-availability, non-toxicity and non-irritability, said Nagarajan. This formulation would have an enormous scope in the treatment of metastatic cancer. Moreover, the components involved are cost-effective and demonstrate good efficacy, and the technique employed is simple, which is the utmost need for drug development, he said.The team of scientists includes M Joyce Nirmala, post doctoral fellow, Vineet Gopakumar, B Tech student, and Latha Durai, Research Scientistall from IIT-Madras.

Read the original post:
IIT-M develops oil-based cancer therapy - Times of India

An Indian American professor has developed the technology behind the Nanolife Disinfectant Tunnel, which successfully uses silver nano-particles to kill off viral infections.

Kattesh Katti, professor of radiology and director of the Institute of Green Nanotechnology at the University of Missouri in Columbia, Mo., told India-West the technology has been tested successfully on COVID-related viruses. Currently, the 8-foot-long tunnel has been deployed at three locations in Chennai, including the Tirumala Tirupati Temple, where thousands of devotees worship each day.

Indias Prime Minister Narendra Modi has placed an order for more tunnels, according to Katti, which are distributed in India through the company Nanolife.

Katti discovered the effectiveness of silver nano-particles in killing off viruses 20 years ago, and commercialized the technology via a hand sanitizer that uses no alcohol or chemicals. The technology was also being used as a cleaning agent in Indian hospitals, he said.

Then the COVID-19 pandemic hit; Katti and the team at Nanolife re-purposed their technology to address the global crisis, which has killed more than 214,000 people around the world, and infected more than three million people.

India, currently on a nationwide quarantine ordered by Modi in March, has a relatively low rate of infection and death from COVID-19: the country had reported 937 deaths and approximately 30,000 infections as of April 28.

But the countrys overcrowded conditions which make required social distancing difficult could drastically raise the number of deaths from the virus, predict Indian epidemiologists.

A country like India really needs more resources, Katti told India-West. The very high population density makes the pandemic significantly more dangerous, he said.

Unlike other disinfecting tunnels currently used in India and some other countries, Nanolifes disinfectant tunnel uses no harmful chemicals, which could be toxic. The technology is based simply on silver nano-particles, water and a proprietary herb that keeps the particles intact, said Katti, adding that the product is used in very low concentrations in the tunnels.

Prof. Jagat Ram of the Postgraduate Institute of Medical Education and Research, Chandigarh, and Prof. JS Thakur, chairman, Covid-19 Prevention Committee at PGI, have questioned the efficacy of disinfecting tunnels, stating that they provide people with a false sense of security. But the tunnels to which they were referring to use sodium hypochlorite, which is known to have several serious side effects. Nanolifes tunnels have no side effects, according to Katti.

The Government of India has banned the export of COVID-related technology, citing the huge need within the country for such products. Thus, for the moment, the Nanolife Disinfectant Tunnel is limited to deployment in India, but Katti is aiming to eventually bring the device to the U.S.

The Dharwad native said he envisions the Nanolife Disinfectant Tunnel in front of railway stations, airports, office buildings, and other large gathering places. Demand far outweighs production capability at the moment, he told India-West.

According to his bio, green nanotechnology is at the focal point of Katti's approach to pursuing research in nanotechnology and molecular medicine as he strongly believes in the total elimination of toxic chemicals in the production of engineered nanoparticles.

He uses phytochemicals occurring naturally within plants and herbs for nano constructs in a variety of applications.

Originally posted here:
Missouri Indian American Professor Develops Disinfecting Tunnel to Kill Viral Infections Using Silver Nano-particles - India West

Apr 29, 2020 06:57 PM EDT

Researchers have made new inroads into understanding aerosol treatments for asthma to help in improvements of the drug in the future. Such innovation can potentially help asthma patients.

Asthma is a disease of the lungs that affects around 330 million people all over the world. It is a major worldwide health concern. Presently, the best treatment form and preparation available with the most beneficial impact are aerosols inhaled directly into the patient's lungs. It is a challenge for researchers because our current knowledge regarding the microstructure of drugs before being converted to aerosol is quite limited.

Such aerosol preparations arecarrier-based DPI or dry powder inhalers, which must be characterized accurately for particle size distribution, surface roughness, flow properties, and fines contents. It is critical to understand the powder formulation's micro-structure, but before the current research, characterization techniques have not given complete information.

Conventional techniques include optical microscopy or OM and laser diffraction or LD. These techniques are limited because the particles are assumed to be spherical and because they provide varying results based on particle dispersion and orientation.

Scientists from theUniversity of Manchesterhave done research that sheds light on this aspect. Using X-Ray Micro-Computer Tomography (or XCT) scanning, the microstructure of the drug's particles have been quantified to the nano-level or scale.

Researchers revealed this 3D microstructure for the first time. It gives the scientific community, medical researchers, and pharmaceutical companies more understanding regarding the drug's behavior when it is aerosolized.

Dr. Parmesh Gajjar, the research's lead author, said that the team was successful in visualizing a 3-D drug-blend to see the interaction between its active ingredient and its non-drug particles. Such insight is essential in the final step of quality control of drug production. It will enable producers to verify the actual drug content in the medicine and help in coming up with better formulations, and thus improve its effectiveness.

The XCT equipment and instruments that the research team utilized is located at the world-leading HMXIF or the Henry Moseley X-ray Imaging Facility. This facility is housed at the University of Manchester. The facility and equipment are capable of analyzing samples at a resolution as small as 50nm.

The research is very important in obtaining knowledge about asthma inhalation medicines, which need aerosolization for generating particles small enough to be absorbable by the lungs. The project studied particles that are tiny enough to be able to reach into the lung's deepest recesses.

The research's novel technological innovation was one of the papers proposed to be presented at the2020 Respiratory Drug Delivery conference(RDD); it was chosen one of the key presentations at the said global conference. The venue of the conference was initially booked at Palm Springs. Still, due to the coronavirus pandemic and the lockdowns it caused, the organizers first opted to make it an online event instead and has currently been canceled until further notice.

The study was published in theEuropean Journal of Pharmaceutics & Biopharmaceuticsand is entitled "3D Characterisation of Dry Powder Inhaler Formulations: Developing X-Ray Micro Computed Tomography Approaches.

2018 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

See the original post:
New Insights in Asthma Medicines May Improve Future Drugs and Treatment - Nature World News

Scientists at SN Bose National Centre for Basic Sciences, Kolkata (SNBNCBS) have developed a safe and cost-effective nanomedicine that promises treatment of a number of diseases by altering oxidative stress in the body. The research may provide a ray of hope in Indias fight against COVID-19, as the nanomedicine can decrease or increase reactive oxygen species in the body, depending on the situation and cure the disease.

The research on nanomedicines may be effective against viral infection. Recently, the institute has shown that the added oxidative stress upon administration of the nanomedicine can break down bilirubin that causes jaundice, providing a cure for this serious ailment.

In a trial on mice, the nanomedicine was found safe and swift, precisely bringing down bilirubin levels within two and a half hours. This ability of controlled enhancement of oxidative stress in mammals paves new potential for the application of nanomedicine in controlling virus infection, including COVID-19.

Link:
SNBNCBS develops nanomedicine to alter oxidative stress; may help in fight against COVID-19 - All India Radio

By Nicole Bergot

A drug can prevent the virus responsible for the COVID-19 pandemic from replicating once inside an infected host, say researchers at the University of Alberta now searching for that magic bullet.

We aim to identify drugs that can be tested for effectiveness and safety in future trials, said Michael Woodside, a professor in the department of physics, using $370,700 in emergency funding from the Canadian Institutes of Health Research (CIHR) to find the elusive drug.

The plan is to screen first for drugs that are already approved for human use that could be repurposed to treat COVID-19 more quickly before broadening the search to potential drugs that are not currently approved.

Woodside explains that the genome of the novel coronavirus is made up of ribonucleic acid (RNA), not DNA so once inside an infected host, the virus inserts its RNA genome into the cell causing the creation of proteins the virus needs to replicate. And for all of this to occur, the novel coronavirus uses a process called programmed ribosomal frameshibing (PRF), a topic that Woodside, as a biophysicist, and his lab have been studying for years.

Researchers using laser tweezers to mimic what happens inside an infected cell were able to identify the mechanism through which PRF is triggered and now they can find molecular compounds to stop it from happening.

Most efforts to find drugs look for compounds that target the viral proteins directly, explains Woodside. Whats different about our approach is that we are targeting the virus through its RNA, rather than the proteins.

Woodside, inside the National Research Council of Canadas Nanotechnology Research Centre right here in Edmonton, is working closely with grad students, American counterparts, and Jack Tuszynski, a biophysics professor also in the department of physics, currently on secondment to the department of oncology in the faculty of medicine and dentistry.

Interdisciplinary research and scientific collaborations are essential to stopping the COVID-19 pandemic, said Woodside. Solutions have to engage expertise and approaches across a wide range of areas to understand the biophysics of the viral molecules, the biology of virus replication, the chemistry of drugs and their interactions with targets, the response of the immune system, the symptoms and epidemiology of the disease, and the response of patients to treatments.

Building and validating a model of the viral RNA for drug screening will occur over the next few months, with screening to identify approved drugs to follow before any potential candidates move toward preclinical tests.

Link:
'Laser tweezers' in nano lab used in search for drug to prevent COVID-19 replication - The Province

The Healthcare Nanotechnology Nanomedicine report provides independent information about the Healthcare Nanotechnology Nanomedicine industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Healthcare Nanotechnology Nanomedicine MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Healthcare Nanotechnology Nanomedicine Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Healthcare Nanotechnology Nanomedicine Market: Products in the Healthcare Nanotechnology Nanomedicine classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Abbott Laboratories, Combimatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Mallinckrodt Plc, Merck & Company Inc., Nanosphere Inc., Pfizer, Inc., Celgene Corporation

Healthcare Nanotechnology Nanomedicine Market Report Covers the Following Segments:

Segment by Type:

BiochipImplant MaterialsMedical TextilesWound DressingOther

Segment by Application:

TherapeuticDiagnosticResearch

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Healthcare Nanotechnology Nanomedicine Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Healthcare Nanotechnology Nanomedicine Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Healthcare Nanotechnology Nanomedicine Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Healthcare Nanotechnology Nanomedicine Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Healthcare Nanotechnology Nanomedicine Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Healthcare Nanotechnology Nanomedicine Market.

Market Forecast:Here, the report offers a complete forecast of the global Healthcare Nanotechnology Nanomedicine Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://industrystatsreport.com/ICT-and-Media/Dynamic-Rsearch-on-Data-Virtualization-Market/Summary

https://industrystatsreport.com/ICT-and-Media/Dynamic-Rsearch-on-Online-Gambling-Market/Summary

https://industrystatsreport.com/ICT-and-Media/Dynamic-Rsearch-on-Data-Virtualization-Market/Summary

Read more:
Cover Corona Outbreak: Healthcare Nanotechnology Nanomedicine Market Size, Share & Trends Analysis Report By Product, By Technology, By...